Objective To retrieve the clinical randomized controlled trials(RCTs)of Compound Kushen Injection(CKI)combined with chemotherapy in the treatment of colorectal cancer(CRC)and to explore its clinical efficacy and safety.Methods RCTs on CKI combined with first-line chemotherapeutic regimen for CRC that have been published in PubMed,Embase,CNKI,CBM,WanFang Data,and VIP were searched from the establishment of databases to September 2023.The original data of the included literatures were collected and organized,and then Stata 14.0 software was used to conduct meta-analysis of the data.Results A total of 20 RCTs were included,involving 1 701 CRC patients.The results suggested that chemotherapy combined with CKI could improve the short-term efficacy and effectiveness of CRC patients(RR =1.120,95%CI:1.054-1.189,P =0.000),reduce the incidence of nausea and vomiting(RR =0.873,95%CI:0.830-0.918,P =0.000),decrease the incidence of decreased white blood cell count(RR =0.864,95%CI:0.821-0.916,P =0.000),reduce the incidence of liver dysfunction(RR = 0.895,95%CI:0.853-0.940,P = 0.000),decrease the incidence of myelosuppression(RR =0.894,95%CI:0.829-0.965,P =0.004),reduce the incidence of neurotoxicity(RR =0.903,95%CI:0.847-0.963,P =0.002),and improve the quality of life score(RR =1.218,95%CI:1.103-1.346,P = 0.000).Conclusion Compared with chemotherapy regimen alone,CKI combined with chemotherapy can better improve clinical efficacy,improve patients'quality of life,and reduce the incidence of adverse events in CRC patients.
维普
万方数据